Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

Inclusion Criteria: * Confirmed Metastatic Melanoma * At least 18 years old * No other active malignancy * Hemoglobin at least 9 * Platelet Count at least 100,000 cells/mm3 * ANC at least 1500 cells/mm3 * AST \& ALT less than 2.5X upper limit of normal * Total bilirubin less than 1.5mg/dL * Creatine less than 1.5 mg/dL * Alkaline phosphatase less than 2.5X upper limit of normal * Life expectancy of at least 12 weeks * ECOG performance status of 0-1 * Patient must provide informed consent * Patient must provide authorization to disclose Exclusion Criteria: * Evidence of active brain metastases * The only evidence of metastasis is lytic or blastic bone metastases * Pre-existing peripheral neuropathy of NCI Toxicity Criteria Scale of grade greater than 2 * Received radiotherapy in last 4wks, except if to a non-target lesion only * Clinically significant concurrent illness * Investigator's opinion that patient unlikely to complete study * Cytotoxic chemotherapeutic agent treatment or investigational drug within previous 4wks * History of allergy/hypersensitivity to study drug * Serious Medical Risk Factors determine by the investigator